UBS has maintained its Buy rating on Eli Lilly, setting a price target at $1,050.00, with particular attention on the upcoming Phase 3 SURPASS-CVOT trial comparing Mounjaro to Trulicity in type 2 ...

Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro (R) (tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be ...

Eli Lilly and Company announced today that the European Commission granted marketing authorisation for Trulicity (R) (dulaglutide) solution for injection. Trulicity, a GLP-1 receptor agonist, is a ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio.

Eli Lilly has lowered the prices of several Zepbound (tirzepatide) doses for patients using the company’s self-pay program. Through a new program, the Zepbound Self Pay Journey Program, self-pay ...

Dulaglutide is marketed by Eli Lilly under the brand name Trulicity for the treatment of type 2 diabetes and is registered for this use in South Africa. It is marketed by Aspen through a ...

Latest Pharmaceuticals and Eli Lilly and Company, Novo Nordisk A/S Stock News As of June 26, 2025, Eli Lilly and Company had a $713.8 billion market capitalization, compared to the Pharmaceuticals ...

Eli Lilly, makers of Mounjaro and Zepbound, also used for weight loss, told CBS News: "Lilly has taken steps to help inform people about the risks posed by counterfeit, fake, and unsafe or ...

Eli Lilly And Co (NYSE:LLY) is seeing robust demand for its non-incretin medicines, notably Verzenio, which grew 32% year-over-year in Q3, aided by higher U.S. prices and a 70% adoption rate in ...

Thank you, Paul, and good morning, everybody. Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings call. I'm Joe Fletcher, senior vice president of investor relations.